Last updated: 11/07/2018 19:12:29
A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
Trial description: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Comparative Clinical Trial Evaluating Fluticasone Propionate/Salmeterol 250/50mcg twice daily via DISKUS to Ipratropium Bromide/Albuterol Sulfate (36mcg/206mcg four times a day) Inhalation Aerosol in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Fluticasone/salmeterol combination (250/50) pro- vides greater improvement in lung function and symptoms than the combination of ipratropium/ albuterol in patients with copd. james F. Donohue, MD', Christopher Kalberg, Phl, Amanda Emmett, MS, Kunal Merchant, PhD, and Katharine Knobil, MD. 69th Annual Meeting of the American College of Chest Physicians 10/25/2003 Orlando, Florida
Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med. 2004;3:173-81
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
fluticasone propionate/salmeterol
Collaborators
Not applicable
Study date(s)
December 2001 to November 2002
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2002-28-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website